

Oxytocinergic Modulation of Threat-Specific Amygdala Sensitization in Humans Is Critically Mediated by Serotonergic Mechanisms

Congcong Liu, Chunmei Lan, Keshuang Li, Feng Zhou, Shuxia Yao, Lei Xu, Ning Yang, Xinqi Zhou, Jiabin Yang, Xue Yong, Yina Ma, Dirk Scheele, Keith M. Kendrick, and Benjamin Becker

ABSTRACT

BACKGROUND: Overarching conceptualizations propose that the complex social-emotional effects of oxytocin (OXT) in humans are partly mediated by interactions with other neurotransmitter systems. Recent animal models suggest that the anxiolytic effects of OXT are critically mediated by the serotonin (5-HT) system, yet direct evidence in humans is lacking.

METHODS: To determine the role of 5-HT in OXT-induced attenuation of amygdala threat reactivity and sensitization/desensitization, we conducted a parallel-group, randomized, placebo-controlled, double-blind experiment during which 121 healthy subjects underwent a transient decrease in 5-HT signaling via acute tryptophan depletion or the corresponding placebo-control protocol before the administration of intranasal OXT or placebo intranasal spray, respectively. Mean and repetition-dependent changes in threat-specific amygdala reactivity toward threatening stimuli (angry faces) as assessed by functional magnetic resonance imaging served as the primary outcome.

RESULTS: No main or interaction effects of treatment on amygdala threat reactivity were observed, yet OXT switched bilateral amygdala threat sensitization to desensitization, and this effect was significantly attenuated during decreased central 5-HT signaling via pretreatment with acute tryptophan depletion.

CONCLUSIONS: The present findings provide the first evidence for a role of OXT in threat-specific amygdala desensitization in humans and suggest that these effects are critically mediated by the 5-HT system. OXT may have a therapeutic potential to facilitate amygdala desensitization, and adjunct upregulation of 5-HT neurotransmission may facilitate OXT's anxiolytic potential.

<https://doi.org/10.1016/j.bpsc.2021.04.009>

The hypothalamic peptide oxytocin (OXT) regulates a broad range of peripheral and central functions (1). Across species, OXT plays an important role in complex social behavior and basal emotion processes, particularly salience and threat processing (2). Overarching conceptualizations of the role of OXT in human social-emotional behavior have proposed that the complex behavioral effects of OXT are partly mediated by interactions with other neurotransmitter systems (3). Such interactions have been evidenced by initial animal models demonstrating that OXT's effects in the domains of pair bonding are partly mediated by dopamine (4), whereas social reward and anxiolytic effects involve interactions with the serotonin (5-HT) system (5–7).

Accumulating evidence further suggests that the anxiolytic properties of OXT are (partly) mediated by the 5-HT system. Direct evidence for a role of 5-HT in OXT's anxiolytic effects has been demonstrated in a seminal rodent model combining genetic editing with OXT infusion (7). This study demonstrated that OXT receptors are expressed in one third of the 5-HT releasing neurons in the raphe nucleus, which represents the

principal source of central 5-HT as well as afferent serotonergic projections to the amygdala (8). More recently, initial studies combined intranasal or intracerebroventricular OXT administration with concomitant molecular imaging of 5-HT neurotransmission in nonhuman primates and humans and reported OXT-induced modulations of serotonergic signaling in regions strongly engaged in salience and threat processing, particularly the amygdala and insula, with further analyses suggesting a central role of the amygdala in the oxytocinergic regulation of 5-HT release (6,9).

To directly examine whether the anxiolytic effects of OXT on threat-related amygdala reactivity in humans are mediated by the 5-HT system, we conducted a parallel-group, randomized, placebo-controlled, double-blind functional magnetic resonance imaging (fMRI) experiment during which 121 healthy male participants underwent either transient decreases in 5-HT signaling (via acute tryptophan depletion [ATD⁺]) or a matched control protocol (ATD⁻) before the administration of intranasal OXT or placebo (PLC). Based on previous animal models, we specifically hypothesized that 1) OXT would dampen amygdala

SEE COMMENTARY ON PAGE 1038

threat reactivity to angry faces relative to placebo and 2) pre-treatment with 5-HT depletion would attenuate OXT-induced dampening of amygdala responses relative to OXT treatment alone.

Amygdala responses show rapid adaptations with repeated stimulus presentations, with both reduced (desensitization) (10–12) and increased (sensitization) reactivity (13–15) being reported depending on the respective amygdala subregions involved and emotional content. Furthermore, a higher retest reliability of repetition-dependent amygdala signal changes was found when compared with mean amplitude measurements, suggesting a particular stable marker for pharmacological imaging [e.g., (16)]. Although a number of previous studies suggest that amygdala sensitization/desensitization is modulated by serotonergic signaling (17) and that OXT may modulate arousal and amygdala habituation in trust and cooperation contexts (18,19), the role of OXT for threat-related habituation is still unclear. Therefore, we additionally explored the interactive effects of OXT and 5-HT on sensitization/desensitization, employing a comparable analysis strategy as for amygdala mean amplitudes. Given that previous rodent models demonstrated that OXT regulates amygdala threat responses via direct hypothalamic-amygdala neuronal projections (20) as well as indirect pathways via OXT receptors expressed on serotonergic raphe neurons (7), we hypothesized that downregulation of serotonergic signaling would decrease but not fully abolish the effects of intranasal OXT on amygdala threat reactivity. Finally, although amygdala desensitization as assessed by the mean of a block difference approach represents a robust and comparably reliable within-subject fMRI index (21), we additionally included an independent dataset to determine the robustness of threat-specific amygdala sensitization/desensitization across samples.

METHODS AND MATERIALS

Participants

A total of 121 right-handed, healthy male participants were enrolled. To reduce variance related to sex differences in the effects of oxytocin on amygdala reactivity (22), only male participants were included. Given the complexity of the design, a pragmatic approach for sample size determination was employed based on a recent fMRI study (23) comparing effects of different OXT dosages on threat-related amygdala activity [for a similar approach, see a recent study comparing OXT with another anxiolytic agent (24)]. For the behavioral and mood analysis, based on initial quality assessments, data from 9 subjects were excluded owing to technical problems during data acquisition, poor performance (accuracy >3 SD from mean accuracy), or exclusion criteria. During subsequent quality assessment of the MRI data, 1 subject was further excluded from the fMRI analyses owing to poor normalization quality (for details see CONSORT flowchart, Figure S1). We used the compromise option in G*power (version 3.1.9.4; <https://www.softpedia.com/get/Science-CAD/G-Power.shtml>) to estimate power using the number of subjects in the main analyses of treatments (two-way analysis of variance [ANOVA]: amino acid mixture × intranasal spray) with an expected medium effect size ($\eta_p^2 = 0.06$), which revealed 87% power.

Study protocols were approved by the ethics committee (University of Electronic Science and Technology of China) and adhered to the latest revision of the Declaration of Helsinki. Written informed consent was obtained, and the study was preregistered on [clinicaltrials.gov](https://clinicaltrials.gov/show/NCT03426176) (<https://clinicaltrials.gov/ct2/show/NCT03426176>, NCT03426176).

Procedure

The present study employed a between-subject, randomized, double-blind pharmacological fMRI design incorporating 4 treatment groups that received combinations of ATD⁺ (ATD⁺ vs. ATD⁻ drink) and intranasal OXT (OXT vs. placebo nasal spray). Participants were instructed to abstain from alcohol and caffeine for 24 hours and from food and drinks (except water) for 12 hours before the experiment. To adhere to the pharmacodynamic profile of the treatments, participants arrived between 7:30 AM and 10:00 AM and underwent fMRI acquisition between 1:30 PM and 4:00 PM. Upon arrival, participants received a standardized protein-poor food for breakfast. After the assessment of pretreatment control variables, participants were administered either a tryptophan-depleted amino acid mixture to induce ATD⁺ or a control drink, which was balanced in tryptophan and thus did not induce acute tryptophan depletion (ATD⁻), followed by a 5-hour resting period to achieve a robust reduction in tryptophan levels. During the resting period, participants were asked to relax, and magazines were provided. Subsequently, control variables were assessed, and 5 hours after the amino acid drink, participants self-administered either OXT (24 IU) or PLC nasal spray (standardized according to previous OXT administration studies) (25). In line with the pharmacokinetic profile of intranasal OXT (23), the fMRI paradigm was scheduled 50 minutes after OXT administration. Control variables were assessed before and after fMRI acquisition (for schematic outline of the experimental protocols, see Figure 1).

Control Variables

To control for between-group differences in depressive symptom load, anxiety, and current stress, the Beck Depression Inventory (26), State-Trait Anxiety Inventory (27), and Perceived Stress Scale (28) were administered before treatment. To assess the effects of treatment on mood during the entire experimental procedure, the Positive and Negative Affect Schedule (29) was repeatedly administered before administration of the amino acid drink (T1) and the nasal spray (T2) as well as immediately before MRI acquisition (T3) and at the end of the experiment (T4).

Serotonin Dietary Manipulation (Oral Administration)

A previously validated dietary drink inducing ATD⁺ and a control protocol (ATD⁻) (30,31) was used to temporarily lower central 5-HT level (ATD⁺ group) in a randomized, double-blind, placebo-controlled, between-subject design (Supplement).

OXT (Intranasal Administration)

OXT nasal spray comprised OXT, glycerin, sodium chloride, and purified water, whereas the PLC nasal spray included identical ingredients except for OXT (both provided in identical

Serotonin Mediates Oxytocin's Anxiolytic Mechanism




Figure 1. Experimental design and treatment protocols. ATD⁺, acute tryptophan depletion; ATD⁻, no acute tryptophan depletion (control treatment for ATD); fMRI, functional magnetic resonance imaging; OXT, oxytocin; PANAS, Positive and Negative Affect Schedule; PLC, placebo (for oxytocin); T, time.

spray bottles by Sichuan Meike Pharmaceutical Co Ltd). In line with previous intranasal OXT administration studies (32), a single dose of 24 international units was administered with 3 puffs per nostril.

Experimental Paradigm

The blocked-design fMRI paradigm has been previously validated and demonstrated to produce robust amygdala responses in response to threatening (angry) faces (21,33). The paradigm consisted of 3 runs, and every run comprised 6 blocks of facial stimuli as well as 2 blocks of nonfacial stimuli serving as nonsocial control stimuli. During the face-processing blocks, a trio of condition-specific (neutral, angry, or happy expressions) facial stimuli was presented, and subjects were required to select one of the two faces (bottom) that was identical to a target face (top). Each block comprised 4 condition-specific trials, balanced for gender. Asian facial stimuli were selected from a standardized Asian facial expression database (34). During the nonsocial control blocks, a trio of simple geometric shapes (circles and ellipses) was presented, and subjects were required to select one of the two shapes (bottom) that matched the target shape presented on the top (Figure 1B). Each control block comprised 4 different shape trios. All blocks were preceded by a brief instruction (face match or shapes match) that lasted 2 seconds. Within each block, each trial was presented for 4 seconds with a variable interstimulus interval of 1–3 seconds (mean, 2 s). The total block length was 24 seconds, and the total paradigm lasted 16 minutes 48 seconds.

MRI Data Acquisition and Processing

MRI data was acquired on a 3T MRI system and preprocessed using routines in SPM 12 (Wellcome Department of Cognitive

Neurology, Institute of Neurology, London, United Kingdom; see the Supplement). On the first level, a general linear model was employed and included condition-specific regressors modeling the experimental conditions, the cue-phase, and the 6 head motion parameters. To examine (de)sensitization effects, a separate first-level model was designed, which additionally modeled the blocks separately. The corresponding design matrices were convolved with the default SPM hemodynamic response function. The design matrices additionally included a high-pass filter to control for low-frequency components and a first-order autoregressive model to account for autocorrelation in the time series. To evaluate our a priori hypotheses, analyses focused on threat-specific brain activity using (angry > neutral faces) as the primary contrast of interest.

Statistical Analysis

Effects on Mean Amygdala Threat Reactivity. Effects on threat-related amygdala reactivity were examined using a standard general linear model approach employing the mean contrast of all angry facial expression blocks relative to neutral faces (angry_{all-block} > neutral_{all-block}). On the second level, effects of treatment were examined by means of mixed ANOVA models including treatments (amino acid mixture, ATD⁺/ATD⁻, and intranasal spray OXT/PLC) as between-subject factors.

Effects on Amygdala Threat Sensitization/Desensitization. Effects on amygdala threat sensitization/desensitization were analyzed using the mean of a block difference model including the first and last block (last block minus first block), which is more sensitive than the means of the regression approach with respect to complex nonlinear dependencies during habituation (35). To this end, amplitude

differences between the first block in the first run and the corresponding last block in the last run were calculated. To separate threat-specific amygdala habituation from nonspecific habituation to facial stimuli [e.g., (36)], the primary outcome employed a subtraction of the neutral facial stimuli ($[\text{angry}_{\text{last-block}} - \text{neutral}_{\text{last-block}}] > [\text{angry}_{\text{first-block}} - \text{neutral}_{\text{first-block}}]$). These contrast images were subjected to second-level mixed ANOVA models including amino acid mixture (ATD⁺ vs. ATD⁻) and intranasal spray (OXT vs. PLC) as between-subject factors.

A Priori Region of Interest and Statistical Thresholding.

In line with our regional a priori hypotheses, previous evidence that the anxiolytic effects of OXT in rodents and humans are mediated by the amygdala, and a central role of the amygdala in OXT-induced 5-HT release in humans (9), analyses focused on the amygdala as a priori region of interest. To this end, a bilateral mask for the entire left and right amygdalae were defined using the Automatic Anatomical Labelling template (37) and employed for familywise error (FWE) correction using a small-volume correction ($p_{\text{FWE}} < .05$). An additional exploratory whole-brain analysis was computed to explore treatment interaction effects in regions outside of the a priori defined region of interest using a whole-brain threshold of $p_{\text{FWE}} < .05$. For post hoc comparisons, individual parameter estimates were extracted from the amygdala mask. To evaluate our hypotheses, post hoc comparisons focused on comparing the treatment groups with the respective PLC-treated reference groups.

Robustness of Threat-Specific Amygdala Sensitization/Desensitization.

To further determine the robustness of threat-specific amygdala sensitization/desensitization, we included data from an independent sample of 25 healthy males who underwent a control protocol (ATD⁻) administration before fMRI acquisition with a similar block design paradigm (for details see the Supplement). In line with the analysis in the original sample, the second-level analysis focused on the sensitization/desensitization contrast ($[\text{angry}_{\text{last-block}} - \text{neutral}_{\text{last-block}}] > [\text{angry}_{\text{first-block}} - \text{neutral}_{\text{first-block}}]$).

RESULTS

Sample Characteristics, Confounders, and Mood

There were no pretreatment group differences in age, depressive symptoms, anxiety, current stress levels, and mood (all $p > .16$; for details see Table 1). Examining effects of treatment on mood during the course of the experiment by means of mixed ANOVA models with amino acid mixture (ATD⁺ vs. ATD⁻) and intranasal spray (OXT vs. PLC) as between-subject factors and time point (T1–T4: pre-oral administration, pre-intranasal administration, pre-fMRI, post-fMRI) as within-subject factor revealed a significant main effect of time on both positive ($F_{3,306} = 20.03$, $p < .001$, $\eta^2_p = 0.164$) and negative ($F_{3,306} = 14.73$, $p < .001$, $\eta^2_p = 0.126$) affect, suggesting a general decrease of mood over the experiment. Moreover, a significant interaction effect of ATD and OXT on negative affect ($F_{1,102} = 7.99$, $p = .006$, $\eta^2_p =$

0.073) was observed, with post hoc analyses suggesting that when the participants received OXT treatment after ATD⁺, they reported higher negative affect as compared with the ATD⁻ condition ($p < .01$), while when participants received PLC treatment after ATD⁺, they reported no significant difference as compared with the ATD⁻ condition ($p = .33$). This suggests that in line with some previous studies using the same acute tryptophan depletion protocols (31), ATD⁺ treatment alone did not affect mood in healthy individuals.

Behavioral Results

Examining accuracy and response times by means of mixed ANOVAs with condition (angry face vs. happy face vs. neutral face vs. geometric shape) as within-subject factor and amino acid mixture (ATD⁺ vs. ATD⁻) and intranasal spray (OXT vs. PLC) as between-subject factors revealed no significant effects of treatment on accuracy and reaction time, arguing against potential confounding effects of treatment on basal attention and vigilance (for details see the Supplement).

Effects on Mean Threat-Related Amygdala Amplitude

We conducted a one-sample t test with the contrast ($\text{angry}_{\text{all-block}} > \text{neutral}_{\text{all-block}}$) to validate the paradigm and found that threatening stimuli induced increased bilateral amygdala activation (for details see the Supplement and Figure S2). Contrary to our hypothesis, no significant main or interaction effects of ATD and OXT on amygdala threat reactivity were observed (contrast $[\text{angry}_{\text{all-block}} > \text{neutral}_{\text{all-block}}]$).

Effects on Amygdala Threat Sensitization/Desensitization

Examination of treatment effects on threat-specific amygdala sensitization/desensitization by means of voxelwise ANOVA models including the between-subject factors treatment (amino acid mixture [ATD⁺ vs. ATD⁻] and intranasal spray [OXT vs. PLC]) revealed a significant time (first block vs. last block) $\times$ treatment interaction effect in the bilateral amygdala (left: MNI $[-21, -3, -15]$, $p_{\text{FWE}} = .008$, $k = 20$, $t_{107} = 3.64$; right: MNI $[18, -3, -15]$, $p_{\text{FWE}} = .019$, $k = 1$, $t_{107} = 3.25$; small volume corrected for the bilateral amygdala mask) (Figure 2). Post hoc comparisons on the extracted parameter estimates from the amygdala mask (contrast of interest, $\text{angry}_{\text{last-block}} - \text{neutral}_{\text{last-block}} > \text{angry}_{\text{first-block}} - \text{neutral}_{\text{first-block}}$) revealed that the PLC-treated reference group (ATD⁻-PLC) demonstrated increased amygdala responses, suggesting threat-specific sensitization rather than habituation of the amygdala. Compared with the reference group, OXT (ATD⁻-OXT) switched amygdala sensitization to desensitization as reflected by significantly decreased threat-specific amygdala responses (false discovery rate-corrected p ($p_{\text{FDR}} < .001$; Cohen's $d = 0.99$), while decreased serotonin signaling by ATD⁺ pretreatment before OXT administration significantly attenuated this effect of OXT (ATD⁻-OXT vs. ATD⁺-OXT, $p_{\text{FDR}} = .038$; Cohen's $d = 0.52$). In addition, there was no significant difference between ATD⁺-PLC group and ATD⁻-PLC group ($t_{53} = 1.05$, $p = .30$). An additional post hoc analysis on the condition-specific parameter estimates ($\text{neutral}_{\text{last-block}} > \text{neutral}_{\text{first-block}}$ and $\text{angry}_{\text{last-block}} > \text{angry}_{\text{first-block}}$, respectively) employing a

Table 1. Sample Characteristics (n = 111)

Characteristics	ATD ⁺ -OXT (n = 28)	ATD ⁺ -PLC (n = 26)	ATD ⁻ -OXT (n = 28)	ATD ⁻ -PLC (n = 29)	p Value
Age, Years	21.89 ± 2.39	21.73 ± 2.66	22.24 ± 2.29	22.10 ± 2.13	.86
STAI-Trait	41.79 ± 8.00	41.00 ± 5.85	38.72 ± 7.97	40.83 ± 7.00	.43
STAI-State	38.77 ± 8.81	35.16 ± 6.36	34.71 ± 8.50	35.43 ± 6.64	.21
BDI	6.07 ± 6.44	8.08 ± 6.05	4.90 ± 6.40	5.21 ± 4.97	.21
PSS	14.50 ± 5.45	15.42 ± 5.25	13.59 ± 4.69	15.41 ± 4.58	.46
PANAS-P (T1)	24.19 ± 7.17	24.08 ± 8.38	24.46 ± 6.95	26.04 ± 8.07	.76
PANAS-N (T1)	15.88 ± 9.18	13.04 ± 6.09	11.75 ± 5.02	13.43 ± 5.95	.16

Values are presented as mean ± SD.


ATD⁺, acute tryptophan depletion; ATD⁻, no acute tryptophan depletion (control treatment for ATD); BDI, Beck Depression Inventory; OXT, oxytocin; PANAS-N, Positive and Negative Affect Schedule–Negative affect; PANAS-P, Positive and Negative Affect Schedule–Positive affect; PLC, placebo (for oxytocin); PSS, Perceived Stress Scale; STAI-TAI, State-Trait Anxiety Inventory; T1, time point 1 (pretreatment assessment).

two-way ANOVA with treatments as between-subject factors aimed at further exploring whether the observed treatment effects were specifically driven by the angry face condition. A lack of significant effects on neutral faces in the context of a significant difference between the ATD⁻-PLC group and ATD⁻-OXT ($p_{FDR} = .003$; Cohen's $d = 0.83$) and between the ATD⁻-OXT and ATD⁺-OXT ($p_{FDR} = .037$; Cohen's $d = 0.55$) for the angry condition ($\text{angry}_{\text{last-block}} > \text{angry}_{\text{first-block}}$) (Figure 3) further confirmed effects on threat-specific sensitization/desensitization.

Additional control analysis examining effects of treatment on sensitization/desensitization to positive stimuli ($\text{happy}_{\text{last-block}} - \text{neutral}_{\text{last-block}} > \text{happy}_{\text{first-block}} - \text{neutral}_{\text{first-block}}$) and nonsocial stimuli ($\text{shapes}_{\text{last-block}} > \text{shapes}_{\text{first-block}}$) did not reveal significant differences, further suggesting threat-specific effects.

Exploratory Whole-Brain Analysis

In line with our hypothesis, the primary analysis focused on the amygdala. In addition, an unrestricted exploratory whole-brain analysis was conducted on the voxel level. Results from this analysis revealed a significant time × treatment effect in cortical midline regions, insula, and the bilateral superior temporal gyrus (for details see the Supplement and Figure S3).



$p_{FDR} < .05$; ***significant post hoc differences at $p_{FDR} < .001$. ATD⁺, acute tryptophan depletion; ATD⁻, no acute tryptophan depletion (control treatment for ATD); FDR, false discovery rate; FWE, familywise error; OXT, oxytocin; PLC, placebo (for oxytocin); SVC, small volume correction.

Robustness and Replicability of Threat-Specific Amygdala Desensitization

Data from an independent validation sample of 25 healthy male subjects was employed to determine the robustness of the threat-specific amygdala sensitization observed in the control group (ATD⁻-PLC). A voxelwise second-level analysis of the sensitization/desensitization contrast ($\text{angry}_{\text{last-block}} - \text{neutral}_{\text{last-block}} > \text{angry}_{\text{first-block}} - \text{neutral}_{\text{first-block}}$) confirmed threat-specific bilateral amygdala sensitization ($p_{FWE} < .001$) in the validation sample (see the Supplement and Figure S4).

DISCUSSION

Overarching conceptualization suggests a modulatory influence of OXT on 5-HT signaling, and animal models demonstrated a functional relevance of this interaction for the anxiolytic potential of OXT. Building on these previous findings, the present pharmacological fMRI study employed an experimental protocol to reduce central 5-HT signaling before the administration of intranasal OXT to determine the role of 5-HT in mediating OXT-induced attenuation of amygdala threat reactivity. In contrast to our hypothesis, no effects on the mean amplitude of amygdala threat reactivity were observed; however, further analyses on repetition-dependent threat-related amygdala reactivity revealed a sensitization of




Figure 3. Condition-specific amygdala sensitization/desensitization. Condition-specific parameter estimates for amygdala sensitization/desensitization for angry and neutral faces. Bars correspond to the extracted estimates for the identified amygdala region and suggest threat-specific differences between the treatment groups. *Significant post hoc differences at $p_{FDR} < .01$; **significant post hoc differences at $p_{FDR} < .05$. ATD⁺, acute tryptophan depletion; ATD⁻, no acute tryptophan depletion (control treatment for ATD); FDR, false discovery rate; OXT, oxytocin; PLC, placebo (for oxytocin).

the bilateral amygdala with repeated presentation of threatening faces after control treatment (ATD⁻-PLC), which was switched to desensitization after OXT administration (ATD⁻-OXT), and showed that this effect of OXT was attenuated after decreased central serotonin signaling via pretreatment with ATD⁺ (ATD⁺-OXT). Together, these findings provide the first evidence that OXT facilitates amygdala threat desensitization and that this effect is (partly) mediated via a 5-HT-dependent mechanism.

In contrast to our hypothesis, no effects of OXT on the mean amplitude of amygdala threat reactivity were observed, which might be related to the specific threat stimuli chosen. We chose angry faces as direct threat stimuli, and while previous studies demonstrated convergent evidence for a serotonergic modulation of amygdala reactivity to angry as well as fearful faces (38), the effects of intranasal OXT on amygdala threat processing appear to depend strongly on the specific emotion of the faces displayed. Whereas previous intranasal OXT studies reported enhanced recognition of fearful faces and attenuated amygdala reactivity toward fearful faces, OXT did not consistently modulate recognition of or amygdala reactivity toward angry facial expressions (39–41). The differences may be explained in the different motivational tendencies inherent to the facial expressions, such that the dominant response to angry expressions is threat avoidance, whereas the dominant response to fearful expressions is approach (42). Likewise, the observation that OXT reduces amygdala habituation to unreciprocated cooperation in men (19) indicates that the effects of OXT on habituation may be domain specific.

The amygdala exhibits rapid adaptations to repeated presentation of salient stimuli, including facial expressions (10), and these changes might be a more reliable marker of

amygdala function as assessed by fMRI activation (16,21). Desensitization (habituation) of amygdala responses has been most consistently reported, but amygdala sensitization may also occur with repeated presentation of particularly salient or aversive stimuli (14). The currently prevailing dual-process framework proposes that the incremental (sensitization) and decremental (habituation) adaptations on the physiological and affective level are based on independent yet interacting processes (43). Sensitization has most consistently been observed in response to repeated presentations of reward- and threat-related stimuli (43), and sustained attention and less habituation to threat, including angry facial stimuli, have been demonstrated on the behavioral level (15,44). Consistently, increased neural responses with repeated presentation of angry emotional stimuli have been reported in limbic regions (15), including the amygdala (14). Partly resembling these previous observations, we found threat-specific amygdala sensitization in the control group (ATD⁻-PLC), while OXT switched the direction of the repetition-dependent adaptation, leading to a threat-specific habituation in this region.

The amygdala is particularly sensitive to social information (45) and exhibits widespread functional interactions with limbic and prefrontal systems [e.g., (46)]. Previous studies in animals have pinpointed anxiolytic effects of OXT to the amygdala (20,47), and in humans, intranasal OXT enhanced communication between the amygdala and prefrontal regulatory regions (48). By modulating anger-related habituation of amygdala reactivity, OXT may facilitate rapid and flexible adaptation to social threat signals (3,48).

In line with a previous rodent model demonstrating that the anxiolytic effects of OXT are critically mediated by the 5-HT system (7), we found that ATD⁺-induced reduction in serotonergic signaling attenuated, but did not fully abolish, the effects of OXT on amygdala threat reactivity. Animal models suggest that the anxiolytic action of OXT is mediated via hypothalamic-amygdala projection neurons (20) as well as OXT-sensitive receptors expressed on serotonergic raphe neurons (7). Whereas initial data suggest that ATD⁺ may reduce peripheral OXT levels in the absence of behavioral effects (49), the combination of ATD⁺ with PLC nasal spray did not produce effects on amygdala reactivity in the present study, arguing against an ATD⁺-induced nonspecific decrease in OXT signaling.

In contrast, molecular imaging studies have demonstrated that intranasal OXT induces central serotonin release (6,9), and ATD⁺ leads to stable and selective reductions in central 5-HT signaling (50), including attenuation of stimulated serotonin release (50,51) and availability of serotonin in presynaptic neurons (52). This suggests that pretreatment with ATD⁺ diminished OXT-induced serotonin release via OXT-sensitive receptors on serotonergic raphe neurons, which in turn attenuated anxiolytic effects mediated by serotonergic raphe-amygdala pathways.

Given the increasing interest in the clinical application of OXT to attenuate anxiety and exaggerated amygdala responses (2,39), the present results have important clinical implications. First, deficient amygdala threat desensitization has been reported in several psychiatric disorders, including anxiety disorders and autism, and may represent a core

pathological mechanism for the development and maintenance of exaggerated anxious arousal (17,53), with the present results indicating that OXT may facilitate amygdala threat habituation. Second, serotonin dysfunction is a core biomarker of anxiety and autism spectrum disorder (54,55). We found that the strength of the effect of OXT on amygdala threat desensitization was mediated by endogenous 5-HT levels, suggesting that individuals with low endogenous serotonergic levels may not fully capitalize on the anxiolytic effects of OXT, and thus combined upregulation of 5-HT and OXT transmission may be needed for optimal facilitation of anxiolytic effects.

Findings of the present study need to be interpreted in the context of the following limitations. First, we employed a between-subject design, which may add heterogeneity to the sample yet control for repeated assessment effects. Future studies should employ crossover designs to validate the robustness of the findings. Second, only male subjects were investigated because of sex differences in 5-HT synthesis rate (56) and the effects of OXT on amygdala reactivity (19,22), and future studies need to determine whether the observed effects generalize to women. Third, tryptophan levels were not assessed in the present study; however, the study adhered to previously validated ATD⁺ protocols, which have been shown to induce robust and selective decreases in 5-HT signaling (30,57). Fourth, blood levels of OXT were not assessed to validate the increase in (peripheral) OXT levels; however, previous studies using identical intranasal administration protocols reported increased blood levels of OXT (58,59). Nevertheless, the examination of blood-level measures, particularly in the combined treatment group, may have revealed important additional information on the interaction of the two systems. Finally, the present study did not include fearful facial expression stimuli. Based on previous studies reporting that intranasal OXT may have pronounced effects on the recognition of and amygdala reactivity toward fearful faces [(39–41; however, see (60–64)] and that neural responses to angry and fearful facial expressions are separable, future studies should include fearful and angry faces to directly compare effects on the divergent approach and avoidance motivation induced by these facial expression (42).

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by the National Key Research and Development Program of China (Grant No. 2018YFA0701400 [to BB]); National Natural Science Foundation of China (Grant No. 91632117 [to BB], 31530032 [to KMK], 31700998 [to SY]); Open Research Fund of the State Key Laboratory of Cognitive Neuroscience and Learning (to BB and YM), Beijing Normal University; and Science, Innovation and Technology Department of the Sichuan Province (Grant No. 2018JY0001 [to BB]).

We thank all subjects who participated in this study.

A previous version of this article was published as a preprint on bioRxiv: <https://doi.org/10.1101/2020.05.20.105684>.

The authors report no biomedical financial interests or potential conflicts of interest.

ClinicalTrials.gov: The Interaction Between Oxytocin and Serotonin; <https://clinicaltrials.gov/ct2/show/NCT03426176>; NCT03426176.

ARTICLE INFORMATION

From the Clinical Hospital of the Chengdu Brain Science Institute (CLI, CLa, FZ, SY, LX, NY, XZ, KMK, BB), School of Life Science and Technology, MOE

Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu; State Key Laboratory of Cognitive Neuroscience and Learning (JY, XY, YM), IDG/McGovern Institute of Brain Research, Beijing Normal University, Beijing; School of Psychology and Cognitive Science (KL), East China Normal University, Shanghai, China; Division of Medical Psychology (DS), Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn; and Department of Psychiatry (DS), School of Medicine & Health Sciences, University of Oldenburg, Oldenburg, Germany.

Address correspondence to Benjamin Becker, Ph.D., at ben_becker@gmx.de.

Received Dec 11, 2020; revised Mar 21, 2021; accepted Apr 12, 2021.

Supplementary material cited in this article is available online at <https://doi.org/10.1016/j.bpsc.2021.04.009>.

REFERENCES

1. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M (2011): Oxytocin and vasopressin in the human brain: Social neuropeptides for translational medicine. *Nat Rev Neurosci* 12:524–538.
2. Neumann ID, Slattery DA (2016): Oxytocin in general anxiety and social fear: A translational approach. *Biol Psychiatry* 79:213–221.
3. Ma Y, Shamay-Tsoory S, Han S, Zink CF (2016): Oxytocin and social adaptation: Insights from neuroimaging studies of healthy and clinical populations. *Trends Cogn Sci* 20:133–145.
4. Young LJ, Wang Z (2004): The neurobiology of pair bonding. *Nat Neurosci* 7:1048–1054.
5. Dölen G, Darvishzadeh A, Huang KW, Malenka RC (2013): Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. *Nature* 501:179–184.
6. Lefevre A, Richard N, Jazayeri M, Beuriet PA, Fieus S, Zimmer L, et al. (2017): Oxytocin and serotonin brain mechanisms in the nonhuman primate. *J Neurosci* 37:6741–6750.
7. Yoshida M, Takayanagi Y, Inoue K, Kimura T, Young LJ, Onaka T, Nishimori K (2009): Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. *J Neurosci* 29:2259–2271.
8. Sengupta A, Bocchio M, Bannerman DM, Sharp T, Capogna M (2017): Control of amygdala circuits by 5-HT neurons via 5-HT and glutamate cotransmission. *J Neurosci* 37:1785–1796.
9. Mottet R, Redouté J, Costes N, Le Bars D, Sirigu A (2014): Switching brain serotonin with oxytocin. *Proc Natl Acad Sci U S A* 111:8637–8642.
10. Breiter HC, Etcoff NL, Whalen PJ, Kennedy WA, Rauch SL, Buckner RL, et al. (1996): Response and habituation of the human amygdala during visual processing of facial expression. *Neuron* 17:875–887.
11. Wright P, Liu Y (2006): Neutral faces activate the amygdala during identity matching. *Neuroimage* 29:628–636.
12. Phillips ML, Medford N, Young AW, Williams L, Williams SCR, Bullmore ET, et al. (2001): Time courses of left and right amygdalar responses to fearful facial expressions. *Hum Brain Mapp* 12:193–202.
13. Hitchcock JM, Sananes CB, Davis M (1989): Sensitization of the startle reflex by footshock: Blockade by lesions of the central nucleus of the amygdala or its efferent pathway to the brainstem. *Behav Neurosci* 103:509–518.
14. Frühholz S, Grandjean D (2013): Amygdala subregions differentially respond and rapidly adapt to threatening voices. *Cortex* 49:1394–1403.
15. Strauss MM, Makris N, Aharon I, Vangel MG, Goodman J, Kennedy DN, et al. (2005): fMRI of sensitization to angry faces. *Neuroimage* 26:389–413.
16. Gee DG, McEwen SC, Forsyth JK, Haut KM, Bearden CE, Addington J, et al. (2015): Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study. *Hum Brain Mapp* 36:2558–2579.
17. Wiggins JL, Swartz JR, Martin DM, Lord C, Monk CS (2014): Serotonin transporter genotype impacts amygdala habituation in youth with autism spectrum disorders. *Soc Cogn Affect Neurosci* 9:832–838.

18. Kéri S, Kiss I (2011): Oxytocin response in a trust game and habituation of arousal. *Physiol Behav* 102:221–224.
19. Chen X, Gautam P, Haroon E, Rilling JK (2017): Within vs. between-subject effects of intranasal oxytocin on the neural response to cooperative and non-cooperative social interactions. *Psychoneuroendocrinology* 78:22–30.
20. Knobloch HS, Charlet A, Hoffmann LC, Eliava M, Khrulev S, Cetin AH, *et al.* (2012): Evoked axonal oxytocin release in the central amygdala attenuates fear response. *Neuron* 73:553–566.
21. Plichta MM, Grimm O, Morgen K, Mier D, Sauer C, Haddad L, *et al.* (2014): Amygdala habituation: A reliable fMRI phenotype. *Neuroimage* 103:383–390.
22. Gao S, Becker B, Luo L, Geng Y, Zhao W, Yin Y, *et al.* (2016): Oxytocin, the peptide that bonds the sexes also divides them. *Proc Natl Acad Sci U S A* 113:7650–7654.
23. Spengler FB, Schultz J, Scheele D, Essel M, Maier W, Heinrichs M, Hurlmann R (2017): Kinetics and dose dependency of intranasal oxytocin effects on amygdala reactivity. *Biol Psychiatry* 82:885–894.
24. Kreuder AK, Scheele D, Schultz J, Hennig J, Marsh N, Dellert T, *et al.* (2020): Common and dissociable effects of oxytocin and lorazepam on the neurocircuitry of fear. *Proc Natl Acad Sci U S A* 117:11781–11787.
25. Guastella AJ, Hickie IB, McGuinness MM, Otis M, Woods EA, Disinger HM, *et al.* (2013): Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. *Psychoneuroendocrinology* 38:612–625.
26. Beck AT, Steer RA, Ball R, Ranieri WF (1996): Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. *J Pers Assess* 67:588–597.
27. Spielberger CD, Gorsuch RL, Lushene RE (1970): Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press.
28. Cohen S, Kamarck T, Mermelstein R (1983): A global measure of perceived stress. *J Health Soc Behav* 24:385–396.
29. Watson D, Clark LA, Tellegen A (1988): Development and validation of brief measures of positive and negative affect: The PANAS scales. *J Pers Soc Psychol* 54:1063–1070.
30. Passamonti L, Crockett MJ, Apergis-Schoute AM, Clark L, Rowe JB, Calder AJ, Robbins TW (2012): Effects of acute tryptophan depletion on prefrontal-amygdala connectivity while viewing facial signals of aggression. *Biol Psychiatry* 71:36–43.
31. Veen FM van der, Evers EAT, Deutz NEP, Schmitt JAJ (2007): Effects of acute tryptophan depletion on mood and facial emotion perception related brain activation and performance in healthy women with and without a family history of depression. *Neuropsychopharmacology* 32:216–224.
32. Kendrick KM, Guastella AJ, Becker B (2018): Overview of human oxytocin research. In: Hurlmann R, Grinevich V, editors. (2018), *Behavioral Pharmacology of Neuropeptides: Oxytocin*, vol. 35:Cham: Springer International Publishing, 321–348.
33. Hariri AR, Tessitore A, Mattay VS, Fera F, Weinberger DR (2002): The amygdala response to emotional stimuli: A comparison of faces and scenes. *Neuroimage* 17:317–323.
34. Gong X, Huang YX, Wang Y, Luo YJ (2011): Revision of the Chinese facial affective picture system. *Chin Ment Health J* 25:40–46.
35. Blackford JU, Allen AH, Cowan RL, Avery SN (2013): Amygdala and hippocampus fail to habituate to faces in individuals with an inhibited temperament. *Soc Cogn Affect Neurosci* 8:143–150.
36. Fischer H, Wright CI, Whalen PJ, McInerney SC, Shin LM, Rauch SL (2003): Brain habituation during repeated exposure to fearful and neutral faces: A functional MRI study. *Brain Res Bull* 59:387–392.
37. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, *et al.* (2002): Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage* 15:273–289.
38. Raab K, Kirsch P, Mier D (2016): Understanding the impact of 5-HTTLPR, antidepressants, and acute tryptophan depletion on brain activation during facial emotion processing: A review of the imaging literature. *Neurosci Biobehav Rev* 71:176–197.
39. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, *et al.* (2010): Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. *Neuropsychopharmacology* 35:2403–2413.
40. Shahrestani S, Kemp AH, Guastella AJ (2013): The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: A meta-analysis. *Neuropsychopharmacology* 38:1929–1936.
41. Tully J, Gabay AS, Brown D, Murphy DGM, Blackwood N (2018): The effect of intranasal oxytocin on neural response to facial emotions in healthy adults as measured by functional MRI: A systematic review. *Psychiatry Res Neuroimaging* 272:17–29.
42. Hammer JL, Marsh AA (2015): Why do fearful facial expressions elicit behavioral approach? Evidence From a combined approach-avoidance implicit association test. *Emotion* 15:223–231.
43. Groves PM, Thompson RF (1970): Habituation: A dual-process theory. *Psychol Rev* 77:419–450.
44. Pérez-Dueñas C, Acosta A, Lupiáñez J (2014): Reduced habituation to angry faces: Increased attentional capture as to override inhibition of return. *Psychol Res* 78:196–208.
45. Goossens L, Kukulja J, Onur OA, Fink GR, Maier W, Griez E, *et al.* (2009): Selective processing of social stimuli in the superficial amygdala. *Hum Brain Mapp* 30:3332–3338.
46. Bickart KC, Dickerson BC, Barrett LF (2014): The amygdala as a hub in brain networks that support social life. *Neuropsychologia* 63:235–248.
47. Viviani D, Charlet A, van den Burg E, Robinet C, Humi N, Abatis M, *et al.* (2011): Oxytocin selectively gates fear responses through distinct outputs from the central amygdala. *Science* 333:104–107.
48. Eckstein M, Scheele D, Patin A, Preckel K, Becker B, Walter A, *et al.* (2016): Oxytocin facilitates Pavlovian fear learning in males. *Neuropsychopharmacology* 41:932–939.
49. Hogenelst K, Schoevers RA, Kema IP, Sweep FCGJ, aan het Rot M (2016): Empathic accuracy and oxytocin after tryptophan depletion in adults at risk for depression. *Psychopharmacology* 233:111–120.
50. Crockett MJ, Clark L, Roiser JP, Robinson OJ, Cools R, Chase HW, *et al.* (2012): Converging evidence for central 5-HT effects in acute tryptophan depletion [published correction appears in *Mol Psychiatry*. 2012;17:470. Campbell-Meiklejohn, D [corrected to Campbell-Meiklejohn, DJ]. *Mol Psychiatry* 17:121–123.
51. Hood SD, Bell CJ, Nutt DJ (2005): Acute tryptophan depletion. Part I: Rationale and methodology. *Aust N Z J Psychiatry* 39:558–564.
52. Coccaro EF, Siever LJ, Kourides IA, Adan F, Campbell G, Davis KL (1988): Central serotonergic stimulation by fenfluramine challenge does not affect plasma thyrotropin-stimulating hormone levels in man. *Neuroendocrinology* 47:273–276.
53. Kleinmans NM, Johnson LC, Richards T, Mahurin R, Greenson J, Dawson G, Aylward E (2009): Reduced neural habituation in the amygdala and social impairments in autism spectrum disorders. *Am J Psychiatry* 166:467–475.
54. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, *et al.* (2007): Reduced serotonin-1A receptor binding in social anxiety disorder. *Biol Psychiatry* 61:1081–1089.
55. Williams K, Brignell A, Randall M, Silove N, Hazell P (2013): Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). *Cochrane Database Syst Rev* 8:CD004677.
56. Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C, *et al.* (1997): Differences between males and females in rates of serotonin synthesis in human brain. *Proc Natl Acad Sci U S A* 94:5308–5313.
57. Crockett MJ, Clark L, Tabibnia G, Lieberman MD, Robbins TW (2008): Serotonin modulates behavioral reactions to unfairness. *Science* 320. 1739–1739.
58. Burri A, Heinrichs M, Schedlowski M, Kruger THC (2008): The acute effects of intranasal oxytocin administration on endocrine and sexual function in males. *Psychoneuroendocrinology* 33:591–600.
59. Gossen A, Hahn A, Westphal L, Prinz S, Schultz RT, Gründer G, Spreckelmeyer KN (2012): Oxytocin plasma concentrations after single

Serotonin Mediates Oxytocin's Anxiolytic Mechanism

- intranasal oxytocin administration – a study in healthy men. *Neuropeptides* 46:211–215.
60. Kou J, Lan C, Zhang Y, Wang Q, Zhou F, Zhao Z, *et al.* (2021): In the nose or on the tongue? Contrasting motivational effects of oral and intranasal oxytocin on arousal and reward during social processing. *Transl Psychiatry* 11:94.
 61. Kou J, Zhang Y, Zhou F, Sindermann C, Montag C, Becker B, *et al.* (2020): A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin. *Psychol Med* 1–10.
 62. Koch SB, van Zuiden M, Nawijn L, Frijling JL, Veltman DJ, Olff M (2016): Intranasal oxytocin administration dampens amygdala reactivity towards emotional faces in male and female PTSD patients. *Neuropsychopharmacology* 41:1495–1504.
 63. Domes G, Heinrichs M, Gläscher J, Büchel C, Braus DF, Herpertz SC (2007): Oxytocin attenuates amygdala responses to emotional faces regardless of valence. *Biol Psychiatry* 62:1187–1190.
 64. Quintana DS, Westlye LT, Alnæs D, Rustan Ø.G, Kaufmann T, Smerud KT, *et al.* (2016): Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial. *Psychoneuroendocrinology* 69:180–188.